Gilead Sciences is currently presiding over a 'Metabolic Divide' that separates the living from the dead by a margin of profit. The company has blocked access to lenacapavir, a breakthrough HIV prevention drug, by refusing to sell it to Doctors Without Borders. Despite touting a deal with the Global Fund, the lack of a national access plan means millions in low-income countries remain excluded from a drug Gilead calls one of the most important scientific breakthroughs of our time.

This blockade is the defining condition of the 'Subscription Body' model. While Novo Nordisk launches high-dose Wegovy for the wealthy in the Global North, Indian generic firms are fighting to flood the Global South with $15 versions of life-saving medicines. The pharmaceutical industry treats human health as a recurring revenue stream rather than a human right.

We see the same logic in the UK, where think tanks urge the government to plan for 'supervising' the workforce rather than expanding the commons. Health is being enclosed behind paywalls and patent thickets. The struggle of patients in the Global South to access lenacapavir is the same struggle as the nurses in Michigan fighting AI-driven billing. It is a fight to reclaim our bodies from the ledger of the pharmaceutical elite.